Physio-Control
This article was originally published in The Gray Sheet
Executive Summary
Lilly reaches agreement in principle to sell its Physio-Control subsidiary to the private equity investment firm Bain Capital. Financial terms of the deal, which is expected to close by Aug. 1, were not disclosed. The companies indicated that management at the external defibrillator manufacturer is likely to remain intact. Regarding Physio-Control's 900 employees, Lilly said that "Bain has a philosophy that is consistent with Lilly's, including personnel policies and programs that recognize the value of employees." Lilly is forming a new company (Guidant) that will include five of its nine medical device/diagnostic businesses and currently is in negotiations for sale of the remaining three businesses -- Hybritech, IVAC and Pacific Biotech ("The Gray Sheet" June 27, p. 17)
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.